Nuveen LLC Purchases New Position in Metsera Inc. $MTSR

Key Points

• Nuveen LLC has acquired 20,317 shares of Metsera Inc. valued at approximately $553,000, according to their recent 13F filing with the SEC.
• Metsera's stock is currently trading at $35.66, showing a 1.5% decline, with a 52-week range between $12.30 and $47.40.
• Analysts have a consensus rating of "Buy" for Metsera, with price targets reaching up to $65.00 from various firms.

Nuveen LLC purchased a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 20,317 shares of the company's stock, valued at approximately $553,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. New York State Common Retirement Fund bought a new stake in Metsera in the 1st quarter valued at $131,000. Invesco Ltd. bought a new stake in Metsera in the 1st quarter valued at $271,000. Deutsche Bank AG bought a new stake in Metsera in the 1st quarter valued at $374,000. Bank of New York Mellon Corp bought a new stake in Metsera in the 1st quarter valued at $884,000. Finally, TD Asset Management Inc bought a new stake in Metsera in the 1st quarter valued at $2,091,000.

Metsera Stock Down 1.2%

NASDAQ:MTSR traded down $0.42 during mid-day trading on Friday, reaching $35.87. 1,520,674 shares of the company were exchanged, compared to its average volume of 1,208,677. Metsera Inc. has a 12 month low of $12.30 and a 12 month high of $47.40. The company has a fifty day moving average of $34.73 and a 200 day moving average of $28.67.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MTSR shares. Bank of America boosted their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Wells Fargo & Company started coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Wall Street Zen raised shares of Metsera from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a report on Wednesday. Finally, Guggenheim upped their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $59.00.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.